Science & technology | Inventing the future

A growing number of governments hope to clone America’s DARPA

They will not succeed unless they adopt the spirit which motivates it

USING MESSENGER RNA to make vaccines was an unproven idea. But if it worked, the technique would revolutionise medicine, not least by providing protection against infectious diseases and biological weapons. So in 2013 America’s Defence Advanced Research Projects Agency (DARPA) gambled. It awarded a small, new firm called Moderna $25m to develop the idea. Eight years, and more than 175m doses later, Moderna’s covid-19 vaccine sits alongside weather satellites, GPS, drones, stealth technology, voice interfaces, the personal computer and the internet on the list of innovations for which DARPA can claim at least partial credit.

This article appeared in the Science & technology section of the print edition under the headline “Cloning DARPA”

The new geopolitics of big business

From the June 5th 2021 edition

Discover stories from this section and more in the list of contents

Explore the edition

More from Science & technology

Black Mamba snake.

High-tech antidotes for snake bites

Genetic engineering and AI are powering the search for antivenins

A person blowing about a pattern in the shape of a brain

Can you breathe stress away?

Scientists are only beginning to understand the links between the breath and the mind


The Economist’s science and technology internship

We invite applications for the 2025 Richard Casement internship


A better understanding of Huntington’s disease brings hope

Previous research seems to have misinterpreted what is going on

Is obesity a disease?

It wasn’t. But it is now

Volunteers with Down’s syndrome could help find Alzheimer’s drugs

Those with the syndrome have more of a protein implicated in dementia